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Within inﬂuenza viral particles, the intricate balance between
host cell binding and sialic acid receptor destruction is carefully
maintained by the hemagglutinin (HA) and neuraminidase (NA)
glycoproteins, respectively.
1 A major outstanding question in
inﬂuenza biology is the function of a secondary sialic acid binding
site on the NA enzyme (Figure 1). This second site was ﬁrst
discovered through HA activity exhibited by the N9 NA in avian
isolates.
2 Subsequent characterization of this strain through escape
mutant mutagenesis experiments localized the HA activity to
residues on the outer rim of the actual NA binding pocket that play
no role in NA catalytic activity.
3 This activity, also termed
hemabsorbing (HB) for its ability to bind red blood cells, was shown
to be transferable to the human N2 subtype by site-directed
mutagenesis.
4 Structural proof for the existence of this secondary
sialic acid binding site was later established through X-ray
crystallography experiments.
5 The conservation of residues com-
prising this secondary site in the NA from avian strains, but not
human or swine, suggested that this feature may play an unknown
biological role, and a careful analysis of individual strains further
indicated positive selection pressure in the HB site within the avian
strains only.
6 Through a series of Brownian dynamics (BD)
simulations of the avian N1 and human N2 enzymes, we have
probed the role of this secondary sialic acid binding site in the
avian N1 subtype. Our results suggest that electrostatic interactions
at the secondary and primary sites in avian NA may play a key
role in the recognition process of the sialic acid receptors and
catalytic efﬁciency
7 of NA.
Eight separate sets of BD simulations were carried out using
the natural substrate sialic acid and the oseltamivir inhibitor
(Supporting Information (SI) Figure S1) and the full tetrameric
crystal structures of avian N1 (A/Vietnam/1203/04)
8 and human
pandemic N2 (A/Tokyo/3/67).
9 BD simulations are able to model
the relative diffusion of two or more biomolecules on biologically
relevant time scales
10,11 and allow the calculation of the second-
order association rate constant of a ligand to a predeﬁned binding
site.
12 In these simulations, the proteins and ligands are free to
translate and tumble through an implicit solvent model of water
that is viscous and contains random ﬂuctuations in accordance with
the ﬂuctuation-dissipation theorem. Intermolecular forces are
exclusively electrostatic in nature and are modeled with a modiﬁed
form of Poisson-Boltzmann electrostatics.
13 In addition, the
condition that the molecular surfaces of the two diffusing particles
cannot overlap is strictly enforced. As is common in BD simula-
tions, internal degrees of freedom are ignored. Given this treatment
of molecular interactions, BD simulations can reliably calculate
association rate constants (kon) that are dominated by long-ranged
electrostatic steering effects but are not well-suited for calculating
dissociation rate constants (koff) that are dominated by shorter ranged
(near van der Waals contacts) and more detailed interactions such
as the hydrophobic effect. Additionally, our model assumes a rigid
body approximation for both the diffusing small molecules as well
as the NA enzymes. This is important to consider in light of the
fact that the avian N1 strain has been shown both crystallographi-
cally
8 and via all-atom molecular dynamics simulations
14 to exhibit
remarkable ﬂexibility in the 150- and 430-loop regions. Still, the
rigid body approximations present in our model allow us to address
the relative association rate of the two molecules to the disparate
sites, for a particular atomic conﬁguration. All simulations were
carried out using the SDA 5 package.
15 Using simple geometric
criteria, we are able to deﬁne separate encounter complexes and
monitor the kinetics of association to both the active site and the
secondary binding site. A close examination of the crystal structures
that contained sialic acid bound to the secondary site allowed us
to deﬁne a set of residue contacts that were used to deﬁne the
reaction criteria in the BD simulations (SI Figure S2). All
simulations were performed under experimental NA reaction condi-
tions: 150 mM NaCl, 310 K, with requisite calcium ions bound;
16
convergence data for the simulations are presented in the SI (SI
Figures S4 and S5). As a control, our computational kon for
oseltamivir using a reaction criterion of 8.0 Å to the active site of
N1 compares well to the experimental 2.52 µM-1 s-1 for N1.
17
While both the 7.5 Å and 8.0 Å criteria are close to the experimental
value, we chose to utilize the 8.0 Å cutoff because many more
encounter events were observed at this distance, providing much
better statistics. This correspondence with experimental data
provides support that these simulations, although highly coarse-
grained, are reasonably modeling the physics relevant to ligand
binding. The secondary site holds an inherent advantage to binding
ligands over the active site given its relatively surface-exposed
position. We have estimated this at approximately 20%, as the ratio
of the secondary site/active site association rate constants at long
reaction criteria (22.5 Å) is approximately 1.2.
We have determined that the fastest kon is for sialic acid binding
to the secondary site in the avian N1 and that it binds to this site
3 orders of magnitude faster than to the active site (Table 1, SI
Figure S7). This is in contrast to the behavior exhibited by the
human N2 enzyme, which has a less than 4-fold difference in
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1, SI Figure S7). These results suggest that electrostatic forces
largely drive the binding of sialic acid to this external secondary
site. The human N2 secondary sialic acid site is more negative in
electrostatic potential, compared to the avian N1, which may
account for the reduced attraction of the negatively charged sialic
acid moieties to this secondary site in the human strain (Figure 1
and SI Figure S3-B). The kon of sialic acid binding to the human
N2 active site is more than an order of magnitude faster than that
of the avian N1 (Table 1, SI Figure S7). This may explain why the
secondary binding site is conserved in avian NA, as it may
compensate for the rather weak kon of sialic acid to the avian N1
active site. Recently, loss of the secondary sialic acid binding sites
has been shown to correlate with reduced hydrolysis of substrates;
7
therefore this additional sialic acid binding site may facilitate the
association of productive encounter complexes with sialic acid
moieties on host cell receptors. If and how ligands are transferred
between the secondary and active sites is difﬁcult to ascertain in
this work given the approximations of the BD simulations, but it
is clear that the natural substrate is initially attracted much more
rapidly to the secondary site. Alternatively, no transfer is required
if the macromolecular substrates are biantennary or are closely
juxtaposed on the host cell surface.
The known NA inhibitor oseltamivir has the fastest kon for the
secondary site of human N2 enzyme (Table 1, SI Figure S7). The
association of oseltamivir to the N2 active site is more than two
times faster than to the N1 site. In the N1 enzyme, oseltamivir
forms a more frequent encounter complex with the secondary site
over the active site, with an almost 2-fold difference (Table 1, SI
Figure S7), whereas an almost 7-fold rate difference is observed
in N2 (Table 1, SI Figure S7). In both strains, oseltamivir exhibits
a larger kon rate constant to the active site than sialic acid. These
results are consistent with the fact that the inhibitor was designed
using the group-2 strains.
18 They also highlight a potential role of
the secondary site in the association with inhibitors, where the loss
of this feature may be a potential mechanism of drug resistance.
Although the secondary sialic acid binding site has previously
been shown to be nonconserved in swine NA strains,
6 the currently
circulating pandemic H1N1 strain (A/California/04/2009) with a
proposed swine origin appears to have retained some of the key
features of the secondary sialic acid binding site. A sequence
analysis showing the residues responsible for sialic acid binding
in the secondary site (Figure 2) indicates that 5 of the 6 residues
responsible for sialic acid binding are conserved in the current H1N1
strain. Moreover, examination of a recently published H1N1 NA
homology model structure
19 shows that the lone nonconserved
residue, a serine to asparagine mutation, preserves the hydrogen
bonding interaction present in the avian N1 strain (SI Figure S6).
The sequence conservation and high number of conserved interac-
tions with the secondary binding site in the pandemic H1N1 strain
indicate that this strain may have retained some features of this
secondary sialic acid binding site. With this in mind, we pursued
similar computational experiments on the pandemic N1 structure.
19
Our results indicate that the currently circulating H1N1 strain
presents an intermediary case of secondary sialic acid association
kinetics, exhibiting a 75-fold difference between the kon rate to the
secondary site and the active site (Table 1, SI Figure S7). This is
a result of both a faster kon to the active site and a slower kon to the
Figure 1. Top view of the N1 tetramer (PDB: 2HTY) depicted in solvent exposed surface area representation; active sites are shown in orange, and
secondary sialic acid binding sites are in green (left panel). Electrostatic potential surfaces of the area outlined in the red box are shown in the remaining
panels for avian N1 (PDB: 2HTY), human N2 (PDB: 1NN2), and the currently circulating pandemic H1N1 strain (homology model presented in ref 19).
Within these surfaces, red represents -10 kcal mol-1 e-1 and blue represents +10 kcal mol-1 e-1. Sialic acid molecules are shown as licorice bound in the
active (yellow) and secondary (cyan) sites.
Table 1. Association Rates (kon) of Ligands to the Active Site and

































a “-a” and “-h” denote avian- or human-derived strains, respectively.
Standard errors of the mean are shown in parentheses.
Figure 2. A sequence comparison of critical secondary sialic acid binding
site residues in the avian N1, human N2, and currently circulating pandemic
strain with possible swine origin is shown. Key conserved residues that
make contact with sialic acid are underlined, as derived from ref 6.
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COMMUNICATIONSsecondary site than in the avian N1 strain. Despite retaining 5 of 6
key sialic acid binding residues in the secondary site, the kon to the
secondary site for the circulating H1N1 strain is roughly 16 times
lower than that for the avian N1 strain. This result indicates possible
lowered HB activity for this secondary sialic acid site and may be
an important event in the emergence of the current pandemic strain.
The human N2 NA from the epidemic strain has a sialic acid
kon to the active site that is ∼8 times faster than that of the pandemic
N1 NA (Table 1, SI Figure S7), whereas the pandemic N1 NA has
a kon to the secondary site that is more than 2 times faster than that
of the human N2 NA. The lower kon for the latter may be due to
the additional charged residues missing in the pandemic strain. Thus,
a complex interplay of structural topology and electrostatics seems
to be important in driving the association of the small molecules
to the various sites on NA.
This BD analysis allows us to speak to the nature of encounter
complex formation events for the terminal sialic acid moieties on
the host cell surface receptors. Understanding that the actual sialic
acid receptors on target host cells are more complex than a single
sialic acid molecule, but recognizing that this terminal group plays
a crucial role in the recognition process, we ﬁnd these results
quantitatively suggest that this secondary binding site may play an
important role in the recognition of these receptors by N1. The
secondary sialic acid binding site, which is adjacent to the actual
NA active site, appears to facilitate the formation of complexes
with the NA protein and the sialic acid receptors and may even
provide supplemental HA activity. Moreover, this site is able to
steer inhibitor binding as well, albeit with a reduced capacity in
N1, and may have potential implications for drug resistance or
optimal inhibitor design. Speciﬁcally, more realistically accounting
for detailed kinetic information, in addition to traditional thermo-
dynamic considerations, could be advantageous for the rational
design of small molecule inhibitors, where the design of inhibitors
that have a faster kon to the active site as compared to the competing
sialic acid substrate would be advantageous.
The exact role of this secondary sialic acid site in the emergence
of a pandemic virus remains to be experimentally determined. The
lack of secondary site conservation in human NA strains to date
may suggest that loss of this feature may actually promote
transmissibility and viral survival among humans, and this has very
recently been shown for the 1918, 1957, and 1968 pandemic
strains.
7 The avian N1, with its strong secondary sialic acid binding
site character, is not highly transmissible among humans, although
when contracted it is highly virulent, with a fatality rate of
∼65%.
20,21 In contrast, the human pandemic N2 is highly transmis-
sible but exhibits reduced virulence, with a fatality rate of ∼1%.
The currently circulating pandemic N1 strain is indeed highly
transmissible but less lethal. Yet unanswered is whether the
enhancement of the secondary sialic acid binding would promote
virulence in the human host. It seems conceivable that the secondary
sialic acid binding site feature could potentially be related to
increased severity in human-contracted avian strains, through the
promotion of modiﬁed recognition events in the respiratory tract,
where avian-like R2,3 linkages on the terminal sialic acid receptors
are found present in humans.
22–24
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